Background: Studying the costs of Chronic Hepatitis B in the different severe liver disease aids evaluation of the cost impact of treatment.
Introduction
Hepatitis B virus (HBV) is one of the majority widespread sources of chronic liver infection in human worldwide. According to Lavanchy (2004) , 15%-40% of chronic hepatitis B patients will develop liver failure or hepatocellular carcinoma [1] . Several studies have shown that CHB imposes substantial costs on patients, families and the society [2] [3] [4] [5] [6] [7] . The costs increase dramatically as the disease progress to more advanced stages [3, 4, 7] . Also, evidence from economic studies contributes to the understanding of potential benefits to society from allocating more resources to prevention and treatment of HBV infections in highly endemic countries such as China, Korea, Hong Kong, and Singapore [3] [4] [5] [6] [7] . However, there is no study of costs together with a prospective assessment of severity of liver disease in CHB patients. Also, few cost studies included indirect cost.
In Thailand, CHB is one of the most common causes of cirrhosis. In 2005, about 2%-7% of Thai adults were infected with HBV [8] . Currently, the antiviral drugs (ARV) were recommended for treatment of CHB in Thailand [9] . However, the lifelong treatment with ARV and regular monitoring in CHB patients will incur considerable healthcare resources [10] . The assessment of changes in the clinical course of CHB diseases during ARV is one of the key points for the management of CHB [11] . Consequently, the study of costs in CHB patients with severe liver disease treated with ARV may demonstrate benefits of ARV on CHB management.
Methods
This research project was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, and Queen Savang Vadhana Memorial Hospital, Chon Buri province, Thailand. The sample size was calculated based on a mean CLDQ score of 150 Thai chronic liver diseases patients from the study by Sobhonslidsuk et al. [12] (mean± standard deviation (SD) = 4.75±1.2 out of 7 scores) those were adjusted them up as 7 scores is equal to one hundred scores (67.86±17.14 scores). The formula is n = z 2 SD 2 / d 2 , whereas: n = sample size, z = 1.96 (95% Confidence Interval), SD = standard deviation, d = margin of error in estimating mean or effect size.
By the formula, the estimated sample size was 54 participants. However, for the reliability of costs' analysis, there were 152 participants in this study.
Participants were all CHB patients of the Queen Savang Vadhana Memorial Hospital out-patient setting from November 2011 to April 2013. Inclusion criteria were 1) male or female aged 18 years and over, 2) criteria for diagnosis and/ or treatment bases on Thailand Consensus Recommendations for Management of Chronic Hepatitis B and C 2009 [9] , 3) participant's willingness to participate voluntarily, and able to provide written informed consent. Exclusion criteria were severe uncontrolled disease involving other organs (heart, kidney, lung) except the liver.
The total cost including the costs of hospitalization comprised direct medical costs, direct non-medical costs, and indirect cost each case per year. Direct medical costs and routine service cost with capital costs were collected from the hospital database, and the direct non-medical cost was collected from patients' self reporting. The indirect cost was assessed in term of work productivity loss. Patients were requested for degree of impairment from the least 0 score to the most 10 scores that were applied to percent multiplied with patients' salary.
Severity of liver disease was assessed by CLDQ three times at initial day (D0), 6 th month (M6), and 12 th (M12) of follow up. CLDQ reflects health in patients' perspective with a high rate of internal consistency (>0.79) [13] with discriminant validity. It has 29 items in 6 domains: abdominal symptoms (AB), fatigue (FA), systemic symptoms (SY), activity (AC), emotional function (EM) and worry (WO) [14] . Its answers result in a seven-point Likert scales with one score means "all of the time" or the most impairment to seven scores mean "none of the time" or the least impairment; therefore, the higher score indicates the better health. It had been translated from the original version to Thai language by Sobhonslidsuk et al. [12] . The Chronbach's alpha of the overall Thai CLDQ scores was 0.96 [12] . In this study, CLDQ was applied by the patients' self-administering and its reliability by split-half Cronbach's alpha was 0.82. The patients were divided into two groups including severe and non-severe liver disease by mean CLDQ score of all patients.
To analyze the effects of ARV treatment on indirect cost and CHB diseases, the patients in severe liver disease group were divided into patients with and without ARV subgroups and classified by their clinical characteristics at D0: HBsAg carrier, uncomplicated CHB, impaired liver function, and cirrhosis/ HCC. Also, the percent of productivity at M12 was compared with D0, and categorized into increasing, stable, and decreasing.
The descriptive statistics were provided with mean (SD) or number (%) as appropriate. The statistics used for comparing frequencies and mean score between the two groups were chi-square and unpaired t-test. For comparing frequencies and mean score within group among D0, M6, and M12, the statistics used were Friedman K related test, and Cochran's Q. A p value less than 0.05 was considered as statistically significant. Data was analyzed with SPSS version 17.
Results
There were 152, 140, and 129 CHB patients participated at D0, M6, and M12. Overall mean (SD) CLDQ score at initial day was 5.5 (0.9) scores; therefore, the patients were divide into the severe liver disease group (CLDQ < 5 scores) and non-severe liver disease group (CLDQ ≥ 5 scores) groups. In the severe liver disease group, number of patients at D0, M6, and M12 were 38, 38, and 33, respectively. Their percent loss at M6 and cumulative percent loss at M12 were 0.0 and 13.1. In the non-severe liver disease group, number of patients at D0, M6, and M12 were 114, 102, and 96, respectively. Their percent loss at M6 and cumulative percent loss at M12 were 10.5 and 15.8%.
Overall, mean (SD) age was 41.6 (11.8) years with half were male (53.5). Majority were employees (67.4%) having mean (SD) salary per month USD 507.4 (1032.5), and had health security (95.3%). Among patients, 27cases (20.9%) developed to cirrhosis and HCC. Nearly half (43.4%) were treated with ARV for hepatitis B infection, and these patients had mean (SD) 22.8 (17.8) months for ARV treatment. Majority (85.7%) of ARV were tenofovir and lamivudine. All liver biomarkers were in normal level. Compared to the non-severe liver disease group, the severe liver disease group had significantly greater mean (SD) age (45.4 (12.4) vs. 39.6 (11.0), p = .008), lesser mean (SD) albumin (4.0 (0.6) vs. 4.2 (0.5), p = .042), and higher number (%) of patients with cirrhosis/HCC (12 (31.6) vs. 59 (51.8), p = .048) (see Table 1 ). [3, 4] costs in nt form the hospital information database that should be more accurate than an average cost based from the national database or a predicted cost from the model. Unlike, most of the previous studies where retrospective analysis, used a model that may result in gross magnification of errors [16] , and most studies were analyzed based on the perspectives of health care system or third party payer which considered only direct medical costs [17] . Second, the work on productivity loss over time was assessed and it could reflect productivity loss of employer or society. Finally, information from this study is essential and beneficial for further analysis on economic appraisals for CHB management.
CHB-related diseases could result to productivity loss especially in patients with cirrhosis. This is the first study that measured work-related disorders in CHB patients that could express productivity loss in monetary value. It provides an understanding of a considerable indirect cost of the CHB patients to the society. In this study, the productivity loss rated in patients' perspective was approximately 10%, and could be more if the disease progress to cirrhosis. This may be related to impairment of physical and psychological function. The findings have shown that patients with cirrhosis and HCC had work loss and died at a one-year follow up even if these patients were already treated. This finding highlighted the importance of prevention of the CHB patient from developing cirrhosis.
Over time, CHB patients with ARV for hepatitis B infection had productivity increasing or indirect cost reducing, accept for the patients with cirrhosis and HCC. These patients tended to have work loss and died because the natural progression of HBV is associated with an increased morbidity and mortality [2, 18] . This study showed that ARV benefits the noncirrhosis CHB patients [19] . Also, previous economic analyses have shown the cost-effectiveness of ARV in CHB patient [19] [20] [21] [22] that could save direct medical costs from progressive liver damages [4] . In addition, in severe CHB cases, the finding showed that ARV cost was less than indirect cost (mean (SD) ARV cost = USD 490.4 (861.3), indirect cost = USD 584.2 (797.0)). Hence, this finding emphasized the importance of early ARV treatment on indirect costs and health impairments of CHB patient that should be considered.
